Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation

Gene Therapy

Volumn 12, Issue 20, 2005, Pages 1534-1538

  Denby, L ^a   Nicklin, S A ^a   Baker, A H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

AAV serotypes; Adeno associated virus; Endothelium; Proteasome; Vascular gene therapy

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GENE PRODUCT; PARVOVIRUS VECTOR; PROTEASOME;

ADENO ASSOCIATED VIRUS; ARTICLE; BINDING AFFINITY; CELL TYPE; DEGENERATION; ENDOTHELIUM CELL; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; LIVER CELL; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN TARGETING; SEROTYPE; SMOOTH MUSCLE FIBER; TRANSGENE; VASCULAR ENDOTHELIUM; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS CAPSID; VIRUS INFECTIVITY;

ANIMALS; AORTA, THORACIC; CELL LINE; CELLS, CULTURED; DEPENDOVIRUS; DNA, VIRAL; ENDOTHELIAL CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; LEUPEPTINS; MICE; MUSCLE, SMOOTH, VASCULAR; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, INBRED WKY; SAPHENOUS VEIN; SEROTYPING; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; ADENO-ASSOCIATED VIRUS 7; MIRIDAE;

EID: 27144473384     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302564     Document Type: Article

References (27)

1. Yla-Herttuala S, Martin J. Cardiovascular gene therapy. Lancet 2000; 355: 213-217.
2. Hedman M et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemai. Phase II results of the Kupoio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677-2683.
3. Grines C et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105: 1291-1297.
4. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993; 72: 1132-1138.
5. French BA et al. Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal procine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation 1994; 90: 2402-2413.
6. George S et al. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neomintimal formation in human saphenous vein. Hum Gene Ther 1998; 9: 867-877.
7. Newman KD et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995; 96: 2955-2965.
8. Maeda Y et al. Gene transfer into vascular cells using adeno-associated virus (AAV) vectors. Cardiovas Res 1997; 35: 514-521.
9. Richter M et al. Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol Genomics 2000; 2: 117-127.
10. Melo LG et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 2002; 105: 602-607.
11. Nicklin S et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mal Ther 2001; 4: 174-181.
12. Pajusola K et al. Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J Viral 2002; 76: 11530-11540.
13. Yan Z et al. Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5 mediated transduction from the apical surfaces of human airway epithelia. Virology 2004; 78: 2863-2874.
14. Duan D et al. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105: 1573-1587.
15. Wilson SH et al. Activated nuclear factor-kappa B is present in the coronary vasculature in experimental hypercholesterolemia. Atheroscelerosis 2000; 148: 23-30.
16. Herrmann J, Gulati R, Napoli C. Oxidative stress-related increase in ubiquitination in early coronary atherosclerosis. FASEB J 2003; 17: 1730-1732.
17. Herrmann J, Ciechanover A, Lerman LO, Lerman A. The ubiquitin-proteasome system in cardiovascular diseases - a hypothesis extended. Cardiovasc Res 2004; 61: 11-21.
18. Baker AH. Targeting AAV vectors. Mol Ther 2003; 4: 433-434.
19. White S et al. Gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 2004; 109: 513-519.
20. Work L et al. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 2004; 9: 198-208.
21. Dishart KL et al. Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: Implications for gene therapy. J Mol Cell Cordial 2003; 35: 739-748.
22. Gao G-P et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-11859.
23. Sarkar R et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Gene Therapy 2004; 103: 1253-1260.
24. Louboutin J et al. Gene transfer into skeletal muscle using novel AAV serotypes. J Gen Med, E-pub ahead of print.
25. Nicol CG et al. Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther 2004; 10: 343-353.
26. Maher PA. Nuclear translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J Cell Biol 1996; 134: 529-536.
27. Sperinde GV, Nugent MA. Heparan sulfate proteoglycans control intracellular processing of bFGF in vascular smooth muscle cells. Biochemistry 1998; 38: 13153-13164.